

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10089146
Filing Date	2002-09-16
First Named Inventor	Wilheim Amberg
Art Unit	1644
Examiner Name	Maher M. Haddad
Attorney Docket Number	065571-0079

U.S.PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	5932730		1999-08-03	Riechers et al	
	2	7109205	B2	2006-09-19	Riechers et al	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S.PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20040048815	A1	2004-03-11	Herr et al	
	2	20040077368	A1	2004-04-22	Geneste et al	
	3	20060142317	A1	2006-06-29	Bakker et al	
	4	20060159678	A1	2006-07-20	Geneste et al	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		Application Number		10089146	10089146 - GAU: 1644	
		Filing Date		2002-09-16		
		First Named Inventor		Wilheim Amberg		
		Art Unit		1644		
		Examiner Name		Maher M. Haddad		
		Attorney Docket Number		065571-0079		

	5	20060235004	A1	2006-10-19	Geneste et al	
	6	20070203338	A1	2007-08-30	Riechers et al	
	7	20070299074	A1	2007-12-27	Netz et al	

If you wish to add additional U.S. Published Application citation information please click the Add button

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	Anderson, V.H., et al., "Mechanical devices" in Cardiovascular Medicine, J.T. Willerson and J.M. Cohn (editors), New York, Edinburgh, London, Churchill Livingstone, 1995, 617-651	<input type="checkbox"/>
	2	Choi, E.T., et al., "Inhibition of neointimal hyperplasia by blocking avB3 integrin with a small peptide antagonist Gp6GRGDSPCA", J. Vasc. Surg. 1994;19:125-34	<input type="checkbox"/>
	3	Corjay, M.H., et al, "avB3, avB5, and Osteopontin Are Coordinately Upregulated at Early Time Points in a Rabbit Model of Neointima Formation" J. Cell Biochem. 75:492-504, 1999	<input type="checkbox"/>

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /MH/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Not for submission under 37 CFR 1.99)</i>	Application Number	10089146	10089146 - GAU: 1644
	Filing Date	2002-09-16	
	First Named Inventor	Wilheim Amberg	
	Art Unit	1644	
	Examiner Name	Maher M. Haddad	
	Attorney Docket Number	065571-0079	

	4	Gawaz, M., et al, "Vitronectin Receptor (avB3) Mediates Platelet Adhesion to the Luminal Aspect of Endothelial Cells" Circulation. 1997;96:1809-1818	<input type="checkbox"/>
	5	McKenna, C.J., et al., "Selective ETA Receptor Antagonism Reduces Neointimal Hyperplasia in a Procine Coronary Stent Model" Circulation. 1998;97:2551-2556	<input type="checkbox"/>
	6	Pratt, R.E., et al., "Pharmacological Strategies to Prevent Restenosis" Circulation. 1996;93:848-852	<input type="checkbox"/>
	7	Title only Rubanyi, G.M., et al., "Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology" Pharmacol Rev. 1994;46:325-415	<input type="checkbox"/>
	8	Sriramaro, P., et al., "Endothelial cell attachment and spreading on human tenascin is mediated by a2B1 and avB3 integrins" J. Cell Scienc. 1993;105:1001-1012	<input type="checkbox"/>
	9	Tam, S.H., et al., "Abciximab (ReoPro, Chimeric 7E3 Fab) Demonstrates Equivalent Affinity and Functional Blockage of Glycoprotein IIb/IIIa and avB3 Integrins" Circulation. 1998;98:1985-1091	<input type="checkbox"/>
	10	Abstract only Yanagisawa, M., et al. "A novel potent vasoconstrictor peptide produced by vascular endothelial cells" Nature 1990;344(6262):114	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Maher Haddad/	Date Considered	10/22/2008
--------------------	----------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.